{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:43:34Z","timestamp":1788533014665,"version":"build-2803163510"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,4]]},"abstract":"\n Background and objectives<\/jats:title>\n Dysregulated mineral metabolism is a common and potentially maladaptive feature of critical illness, especially in patients with AKI, but its association with death has not been comprehensively investigated. We sought to determine whether elevated plasma levels of the osteocyte-derived, vitamin D\u2013regulating hormone, fibroblast growth factor 23 (FGF23), are prospectively associated with death in critically ill patients with AKI requiring RRT, and in a general cohort of critically ill patients with and without AKI.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n \n We measured plasma FGF23 and other mineral metabolite levels in two cohorts of critically ill patients (\n n<\/jats:italic>\n =1527). We included 817 patients with AKI requiring RRT who enrolled in the ARF Trial Network (ATN) study, and 710 patients with and without AKI who enrolled in the Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study. We hypothesized that higher FGF23 levels at enrollment are independently associated with higher 60-day mortality.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In the ATN study, patients in the highest compared with lowest quartiles of C-terminal (cFGF23) and intact FGF23 (iFGF23) had 3.84 (95% confidence interval, 2.31 to 6.41) and 2.08 (95% confidence interval, 1.03 to 4.21) fold higher odds of death, respectively, after adjustment for demographics, comorbidities, and severity of illness. In contrast, plasma\/serum levels of parathyroid hormone, vitamin D metabolites, calcium, and phosphate were not associated with 60-day mortality. In the VALID study, patients in the highest compared with lowest quartiles of cFGF23 and iFGF23 had 3.52 (95% confidence interval, 1.96 to 6.33) and 1.93 (95% confidence interval, 1.12 to 3.33) fold higher adjusted odds of death.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Higher FGF23 levels are independently associated with greater mortality in critically ill patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.10810917","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T20:40:32Z","timestamp":1520541632000},"page":"531-541","source":"Crossref","is-referenced-by-count":52,"title":["Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients"],"prefix":"10.2215","volume":"13","author":[{"given":"David E.","family":"Leaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Siew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele F.","family":"Eisenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finnian R.","family":"Mc Causland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Alp Ikizler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine B.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adit A.","family":"Ginde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kellum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7334-5400","authenticated-orcid":false,"given":"Paul M.","family":"Palevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut S.","family":"Waikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0272-6386(01)80116-5","article-title":"Hypocalcemia: A pervasive metabolic abnormality in the critically ill.","volume":"37","author":"Zivin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMc0809996","article-title":"Vitamin D deficiency in critically ill patients.","volume":"360","author":"Lee","year":"2009","journal-title":"N Engl J Med"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2215\/CJN.00550112","article-title":"FGF-23 levels in patients with AKI and risk of adverse outcomes.","volume":"7","author":"Leaf","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrendo.2010.226","article-title":"Antibacterial effects of vitamin D.","volume":"7","author":"Hewison","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.","volume":"26","year":"2000","journal-title":"Nat Genet"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/ki.2010.313","article-title":"Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.","volume":"78","author":"Hasegawa","year":"2010","journal-title":"Kidney Int"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD.","volume":"25","author":"Scialla","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1681\/ASN.2016080836","article-title":"Fibroblast growth factor 23 levels associate with aki and death in critical illness.","volume":"28","author":"Leaf","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMoa0802639","article-title":"Intensity of renal support in critically ill patients with acute kidney injury.","volume":"359","author":"Palevsky","year":"2008","journal-title":"N Engl J Med"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1378\/chest.15-0169","article-title":"Clinical characteristics and outcomes are similar in ards diagnosed by oxygen saturation\/fio2 ratio compared with pao2\/fio2 ratio.","volume":"148","author":"Chen","year":"2015","journal-title":"Chest"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0895-4356(99)00102-X","article-title":"Analysis of case-cohort designs.","volume":"52","author":"Barlow","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","article-title":"Coupling fibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease.","volume":"23","author":"Wolf","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1373\/jalm.2016.022467","article-title":"Stability of fibroblast growth factor 23 in human plasma.","volume":"1","author":"Cui","year":"2017","journal-title":"J Appl Lab Med"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1373\/clinchem.2010.161174","article-title":"Quantification of 1\u03b1,25-dihydroxy vitamin D by immunoextraction and liquid chromatography-tandem mass spectrometry.","volume":"57","author":"Strathmann","year":"2011","journal-title":"Clin Chem"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/ndt\/gfu051","article-title":"Plasma inflammatory and apoptosis markers are associated with dialysis dependence and death among critically ill patients receiving renal replacement therapy.","volume":"29","author":"Murugan","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: Issues and guidance for practice.","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: A severity of disease classification system.","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"B23-20230813","first-page":"1","article-title":"Kdigo clinical practice guideline for acute kidney injury.","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2307\/2533444","article-title":"Robust variance estimation for the case-cohort design.","volume":"50","author":"Barlow","year":"1994","journal-title":"Biometrics"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/ndt\/gfu063","article-title":"Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly.","volume":"29","author":"Chudek","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2110-5820-1-21","article-title":"FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study.","volume":"1","author":"Zhang","year":"2011","journal-title":"Ann Intensive Care"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1073\/pnas.0902006107","article-title":"Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.","volume":"107","author":"Goetz","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00424-007-0231-5","article-title":"Biological activity of FGF-23 fragments.","volume":"454","author":"Berndt","year":"2007","journal-title":"Pflugers Arch"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/jbmr.3197","article-title":"Therapeutic effects of fgf23 c-tail fc in a murine pre-clinical model of x-linked hypophosphatemia via the selective modulation of phosphate reabsorption.","volume":"32","author":"Johnson","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy.","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"E426","DOI":"10.1152\/ajpendo.00264.2014","article-title":"FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.","volume":"307","author":"Silswal","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41598-017-02709-w","article-title":"FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts.","volume":"7","author":"Smith","year":"2017","journal-title":"Sci Rep"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney Int"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jbmr.1740","article-title":"Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.","volume":"28","author":"Bacchetta","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI83470","article-title":"FGF23 signaling impairs neutrophil recruitment and host defense during CKD.","volume":"126","author":"Rossaint","year":"2016","journal-title":"J Clin Invest"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"R154","DOI":"10.1186\/cc5086","article-title":"Causes of death and determinants of outcome in critically ill patients.","volume":"10","author":"Mayr","year":"2006","journal-title":"Crit Care"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J Clin Invest"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/CCM.0b013e318206ccdf","article-title":"Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill.","volume":"39","author":"Braun","year":"2011","journal-title":"Crit Care Med"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"e64348","DOI":"10.1371\/journal.pone.0064348","article-title":"Serum 1,25-dihydroxyvitamin D: An outcome prognosticator in human sepsis.","volume":"8","author":"Nguyen","year":"2013","journal-title":"PLoS One"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1172\/JCI81928","article-title":"CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders.","volume":"126","author":"Bai","year":"2016","journal-title":"J Clin Invest"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2015.12.035","article-title":"Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery.","volume":"89","author":"Leaf","year":"2016","journal-title":"Kidney Int"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.2014.13204","article-title":"Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: The VITdAL-ICU randomized clinical trial.","volume":"312","author":"Amrein","year":"2014","journal-title":"JAMA"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000439144","article-title":"Choice of reference serum creatinine in defining acute kidney injury.","volume":"131","author":"Siew","year":"2015","journal-title":"Nephron"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201804000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:09Z","timestamp":1786369329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201804000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.10810917","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,8]]}}}